New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
10:00 EDTFRED, TFM, VIVO, WIN, RDC, ESV, VRTX, BRY, SHW, RAH, REN, UTI, SDRL, CTLOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CenturyLink (CTL) downgraded to Neutral from Overweight at Piper Jaffray... Ensco (ESV) downgraded to Hold from Buy at Deutsche Bank... Fred's (FRED) downgraded to Neutral from Buy at SunTrust... Ralcorp (RAH) downgraded to Neutral from Buy at UBS... Rowan Companies (RDC) downgraded to Hold from Buy at Deutsche Bank... Seadrill (SDRL) downgraded to Hold from Buy at Deutsche Bank... Sherwin-Williams (SHW) downgraded to Neutral from Buy at Nomura... Windstream (WIN) downgraded to Underweight from Neutral at Piper Jaffray... Universal Technical (UTI) downgraded to Underperform from Market Perform at BMO... Barry Petroleum (BRY) downgraded to Market Perform from Outperform at BMO Capital... Meridian Bioscience (VIVO) downgraded to Underperform from Neutral at Wedbush... Resolute Energy (REN) downgraded to Market Perform from Outperform at BMO Capital... Vertex (VRTX) downgraded to Hold from Buy at Argus... The Fresh Market (TFM) downgraded to Hold from Buy at Deutsche Bank.
News For CTL;ESV;FRED;RAH;RDC;SDRL;SHW;WIN;UTI;BRY;VIVO;REN;VRTX;TFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
10:40 EDTTFMThe Fresh Market says board looking at internal, external CEO candidates
Subscribe for More Information
10:36 EDTVRTXOptions with decreasing implied volatility
Options with decreasing implied volatility: FOLD WLL WBAI ASPS GES PSEC CTRP LNCO VRTX ARP
10:04 EDTFREDFred's to acquire Reeves-Sain Drug Store and EntrustRx specialty pharmacy
Fred's announced that it has signed an agreement to acquire Reeves-Sain Drug Store, a private specialty and retail pharmacy company based in the greater Nashville, Tennessee area. The acquisition includes both EntrustRx, a specialty pharmacy operation that has a strong regional presence in the Southeast serviced from facilities in Spring Hill, Tennessee and Columbus, Mississippi, as well as the single Reeves-Sain retail pharmacy in Murfreesboro, Tennessee. Under the terms of the agreement, Fred's will acquire EntrustRx and the Reeves-Sain retail pharmacy for approximately $66M, comprising $53M in cash and a $13M note payable. Fred's expects to utilize available cash and borrowings under its revolving loan and credit agreement to fund the transaction, which is expected to close in April 2015 subject to customary closing conditions. Fred's anticipates that the deal will be accretive to earnings per share in the first full year following closing.
March 23, 2015
16:20 EDTVRTXOn The Fly: Closing Wrap
Stocks on Wall Street opened in relatively quiet fashion and remained that way throughout the session until a sharp selloff in the closing minutes. For most of the day the averages moved in a narrow range, as the Dow broke its streak of consecutive days with triple digit moves. Like stocks, the oil markets had a quiet session that stood out amid the recent volatility in crude prices. A late day drop prevented the major stock indexes from adding to the big gains they'd notched on Friday. ECONOMIC EVENTS: In the U.S., the Chicago Fed's national activity index fell to -0.11 in February, below expectations for a reading of 0.10. Existing home sales rose 1.2% to a 4.88M rate in February, which was below the consensus forecast for them to grow 2% to a 4.92M unit rate. COMPANY NEWS: Shares of Kansas City Southern (KSU) declined $9.21, or 7.96%, to $106.48 after the railroad operator lowered its fiscal year revenue guidance to reflect slower year-to-date carload growth primarily from the energy sector, along with a continued deterioration in the value of the Mexican peso against the U.S. dollar and lower fuel surcharge revenues driven by lower WTI prices. The revenue warning appeared to weigh on others in the rail industry as well, with Union Pacific (UNP) falling $4.67, or 3.98%, to $112.78, Norfolk Southern (NSC) dropping $3.87, or 3.5%, to $106.56 and Canadian National (CNI) sliding $1.13, or 1.65%, to $67.24. MAJOR MOVERS: Among the notable gainers was ImmunoGen (IMGN), which gained $1.25, or 16.8%, to $8.69 after Takeda (TKPYY) licensed rights to use the company's antibody drug conjugate technology. Also higher was Tenet Healthcare (THC), which rose $2.45, or 4.94%, to $52.07 after agreeing to combine its short-stay surgery and imaging center assets into a new joint venture with United Surgical Partners International. Tenet will initially own 50.1% of the joint venture and will consolidate its financial results and will have a path to full ownership of USPI over the next five years through a put/call structure, the company noted. Among the noteworthy losers was MEI Pharma (MEIP), which plunged $4.37, or 69.37%, to $1.93 and was downgraded by at least four Wall Street research firms after the combination of Pracinostat and azacitidine showed no difference in the rate of complete remission, the primary endpoint of a Phase II study, compared to azacitidine alone. Also lower were shares of Vertex (VRTX), which fell $5.21, or 3.98%, to $125.79 after reporting data from a study evaluating VX-661 in combination with ivacaftor in cystic fibrosis that JPMorgan said was generally below expectations. INDEXES: The Dow fell 11.61, or 0.06%, to 18,116.04, the Nasdaq lost 15.44, or 0.31%, to 5,010.97, and the S&P 500 dropped 3.68, or 0.17%, to 2,104.42.
12:17 EDTVRTXOn The Fly: Midday Wrap
Subscribe for More Information
10:18 EDTVRTXVertex data not a surprise given recent commentary, says JPMorgan
JPMorgan said Vertex's VX-661 top-line Phase 2 data was generally below expectations but should not be too surprising given recent management commentary. The firm said its thesis remains unchanged and believes few biotechs offer a comparable level of competitive dominance and substantial earnings leverage as Vertex and reiterated its Overweight rating.
10:14 EDTVRTXVertex weakness a buying opportunity, says Piper Jaffray
Piper Jaffray said it views the Phase II study evaluating VX-661 in combination with ivacaftor in CF as too small and too short to derive meaningful conclusions and would use today's weakness following the data as a buying opportunity ahead of approval for KALYDECO + lumacaftor homozygous F508del-CFTR mutation patients, noting that the PDUFA date for the indication is July 5. The firm keeps an Overweight rating and $146 price target on Vertex shares, which are down 4.3% to $125.35 in morning trading.
10:00 EDTSHWOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:38 EDTVRTXVertex shares defended at CRT Capital
Subscribe for More Information
09:37 EDTVRTXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
09:28 EDTVRTXOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTVRTXLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:47 EDTVRTXVertex says VX-661, ivacaftor generally well tolerated in 12-week Phase 2 study
Vertex Pharmaceuticals announced data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation. The study evaluated two doses of VX-661 in combination with ivacaftor. The primary endpoint of the study was safety. The study showed that the combination regimen was generally well tolerated, and all patients completed 12 weeks of treatment. The most common adverse events were pulmonary exacerbation, which occurred in 38% of all patients who received VX-661 and 44% of those who received placebo, and cough, which occurred in 33% of all patients who received VX-661 and 39% of those who received placebo. Secondary endpoints evaluated the effect of the combination on lung function, and the mean within-group absolute improvement from baseline in ppFEV1 for those who received 100 mg of VX-661 in combination with ivacafto was 4.4 and 3.0 percentage points at week 4 and through 12 weeks of treatment, respectively. Consistent with prior Phase 2 studies that evaluated 4 weeks of treatment with VX-661 in combination with ivacaftor, this study showed a rapid improvement in lung function within four weeks of treatment, and after patients completed treatment, lung function returned to baseline. These safety and efficacy data, together with other data from multiple previously completed Phase 2 studies of VX-661, support Vertex’s ongoing Phase 3 program of VX-661 in combination with ivacaftor. The Phase 3 program is evaluating VX-661 in combination with ivacaftor and consists of four Phase 3 studies, including a study in people with two copies of the F508del mutation that began enrollment in February. The other three studies will enroll people with CF who have one copy of the F508del mutation and a second mutation that is either a gating mutation, residual function mutation or a mutation that results in minimal CFTR function.
06:34 EDTSHWSherwin-Williams downgraded to Sell from Neutral at UBS
Subscribe for More Information
March 20, 2015
15:25 EDTSDRLSeadrill volatility at three-month low
Subscribe for More Information
07:19 EDTRDCWhite House expected to unveil fracking rules today, WSJ says
Subscribe for More Information
March 19, 2015
18:11 EDTRDCRowan Companies reports February fleet activity
Subscribe for More Information
March 18, 2015
10:18 EDTSHWEvercore ISI to hold a summit and tour
Subscribe for More Information
March 17, 2015
10:02 EDTWINHigh option volume stocks
High option volume stocks: NGL ARCO ENR OIL SNI ESPR CYH WIN CRZO DISH
09:34 EDTWINActive equity options trading on open
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use